Salvage Liver Transplant in the Treatment of a Child With Local Recurrence of Hepatoblastoma

Gümüş, Ersin; Gülşen, Hayriye Hizarcıoğlu; Özen, Hasan; Orhan, Dıclehan; Varan, Ali; Dincer, Hilmi Anil; Doğrul, Ahmet

doi:10.6002/ect.pediatricsymp2022.o21

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evans stage for the 18 reported was I-2, II-1, III-5, and IV-10. Five additional patients had pretext staging of I-1, II-1, and III-3 10,[12][13][14][15] . AFP levels at diagnosis ranged from 455 to 2.3 million ng/ mL (median: 80,000 ng/mL).…”

Section: Resultsmentioning

confidence: 99%

The Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein–Positive Hepatoblastoma

Davini,

Hastings,

Feusner

2024

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Hepatoblastoma is the most common liver malignancy in children. Treatment typically involves surgery and cisplatin-based chemotherapy. After therapy completion, children undergo repetitive surveillance imaging to screen for relapse, which occurs in <12% of cases. Monitoring for relapse has gradually shifted to serial determination of serum alpha-fetoprotein (AFP) alone as most cases have AFP elevation at the time of relapse. Little primary data supports, such a practice, however, and herein we present both our institutional experience with relapsed hepatoblastoma and a careful review of published literature on this topic. While serial AFP monitoring may suffice for most patients, certain clinical characteristics should give pause to the practitioner, when considering posttreatment monitoring with serum AFP alone.

show abstract